Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain
associated with chronic pancreatitis.
Secondary objectives were:
- to assess the safety and tolerability of REGN475/SAR164877 in patients with chronic
pancreatitis pain;
- to characterize the pharmacokinetic, pharmacodynamic, and immunogenicity profiles of
REGN475/SAR164877 in this population;
- to measure the change in the total daily dose of rescue medications required.